[go: up one dir, main page]

NO20004583L - Krystallinsk form av paroxetine - Google Patents

Krystallinsk form av paroxetine

Info

Publication number
NO20004583L
NO20004583L NO20004583A NO20004583A NO20004583L NO 20004583 L NO20004583 L NO 20004583L NO 20004583 A NO20004583 A NO 20004583A NO 20004583 A NO20004583 A NO 20004583A NO 20004583 L NO20004583 L NO 20004583L
Authority
NO
Norway
Prior art keywords
paroxetine
crystalline form
free
crystalline
therapy
Prior art date
Application number
NO20004583A
Other languages
English (en)
Other versions
NO20004583D0 (no
Inventor
Andrew Simon Craig
Neal Ward
Wilson Mcilwaine
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9805581.7A external-priority patent/GB9805581D0/en
Priority claimed from GBGB9813054.5A external-priority patent/GB9813054D0/en
Priority claimed from GBGB9817115.0A external-priority patent/GB9817115D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20004583D0 publication Critical patent/NO20004583D0/no
Publication of NO20004583L publication Critical patent/NO20004583L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ren, løsningsmiddel-fri, for eksempel krystallinsk, fri paroxetine-base; og dens anvendelse i terapi for å behandle depresjon.
NO20004583A 1998-03-16 2000-09-14 Krystallinsk form av paroxetine NO20004583L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9805581.7A GB9805581D0 (en) 1998-03-16 1998-03-16 Novel compounds
GBGB9813054.5A GB9813054D0 (en) 1998-06-17 1998-06-17 Novel compounds
GBGB9817115.0A GB9817115D0 (en) 1998-08-06 1998-08-06 Novel compounds
PCT/GB1999/000793 WO1999047519A1 (en) 1998-03-16 1999-03-16 Crystalline form of paroxetine

Publications (2)

Publication Number Publication Date
NO20004583D0 NO20004583D0 (no) 2000-09-14
NO20004583L true NO20004583L (no) 2000-09-15

Family

ID=27269245

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004583A NO20004583L (no) 1998-03-16 2000-09-14 Krystallinsk form av paroxetine

Country Status (18)

Country Link
EP (1) EP1064282A1 (no)
JP (1) JP2002506865A (no)
KR (1) KR20010041947A (no)
CN (1) CN1300286A (no)
AP (1) AP2000001907A0 (no)
AU (1) AU2847199A (no)
BG (1) BG104839A (no)
BR (1) BR9908825A (no)
CA (1) CA2323896A1 (no)
EA (1) EA200000946A1 (no)
HU (1) HUP0101215A3 (no)
ID (1) ID27596A (no)
IL (1) IL138390A0 (no)
NO (1) NO20004583L (no)
PL (1) PL342931A1 (no)
SK (1) SK13622000A3 (no)
TR (1) TR200002675T2 (no)
WO (1) WO1999047519A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion

Also Published As

Publication number Publication date
EP1064282A1 (en) 2001-01-03
BG104839A (en) 2001-09-28
HUP0101215A2 (hu) 2002-04-29
KR20010041947A (ko) 2001-05-25
TR200002675T2 (tr) 2000-12-21
EA200000946A1 (ru) 2001-02-26
NO20004583D0 (no) 2000-09-14
BR9908825A (pt) 2000-11-21
ID27596A (id) 2001-04-12
CA2323896A1 (en) 1999-09-23
CN1300286A (zh) 2001-06-20
PL342931A1 (en) 2001-07-16
AU2847199A (en) 1999-10-11
IL138390A0 (en) 2001-10-31
AP2000001907A0 (en) 2000-09-30
JP2002506865A (ja) 2002-03-05
HUP0101215A3 (en) 2002-05-28
WO1999047519A1 (en) 1999-09-23
SK13622000A3 (sk) 2001-03-12

Similar Documents

Publication Publication Date Title
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
BR9707233A (pt) Fenantridinas
NO983189L (no) Nye substituerte imidazolforbindelser
TR200103216T2 (tr) Pirimidinon bileşimleri
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
NO975716L (no) Imidazolforbindelser
AU8112101A (en) Non-imidazole aryloxypiperidines
NO952132D0 (no) Farmakologiske aktive pyridin-derivater og deres fremstilling
BR0011130A (pt) Inibidores de metaloproteases
DK0744944T3 (da) Transdermale terapeutiske systemer indeholdende kønssterioder
MXPA03001267A (es) Ariloxialquilaminas sin imidazol.
ATE400258T1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
SE9802208D0 (sv) Novel compounds
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
MXPA04004503A (es) Derivados de piperina y su uso como moduladores de actividad receptora de quimiocina (especialmente ccr5).
DE69525740D1 (de) Spezielle halofantrinhaltige Zusammensetzungen
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
TR200403001T3 (tr) Lovastatin ve simvastatinin, azaltılmış dimerik katışkı seviyelerine sahip olacak şekilde arıtılması için bir işlem
NO20004583L (no) Krystallinsk form av paroxetine
NO20006547L (no) Salter av paroxetine
SE9802209D0 (sv) Novel compounds
NZ515531A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
TR200002939T2 (tr) Paroksetin maleat
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
TR199802496T2 (xx) Konjestif kalp yetmezli�ini tedavi i�in form�lasyon.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application